BVX 0918A
Alternative Names: BVX-0918; BVX-0918ALatest Information Update: 13 Mar 2024
At a glance
- Originator BioVaxys
- Class Antineoplastics; Cancer vaccines; Immunotherapies; Protein vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Ovarian cancer
Most Recent Events
- 07 Mar 2024 BioVaxys plans a phase I trial for Ovarian cancer (Late stage disease, Second line therapy or greater) in the Spain by 2024
- 16 Mar 2023 BioVaxys plans a phase I/II trial for Ovarian cancer (Late-stage disease, Combination therapy) in European Union in early 2022
- 10 Nov 2022 Preclinical studies are still underway in Ovarian cancer in Canada